{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:54Z","timestamp":1787027034947,"version":"build-2736575974"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the availability, price levels, affordability, and utilisation of targeted drugs for pulmonary arterial hypertension (PAH) in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study utilized a retrospective longitudinal design, based on drug procurement data from 859 public hospitals in China, covering the period from January 2019 to December 2023. Accessibility of 11 PAH-targeted therapies was evaluated across three key dimensions: availability (proportion of hospitals stocking the drug), price level (the Defined Daily Dose cost, namely, DDDc = Total annual drug expenditure\/DDDs of the drug), and affordability (out-of-pocket expenses as a percentage of household disposable income).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While there was a significant overall improvement in the accessibility of PAH-targeted drugs, structural disparities in accessibility were evident across different drug types, hospital tiers, and between urban and rural areas, as well as among income groups. Availability data showed that tertiary hospitals had significantly better access to NMI-negotiated drugs than secondary hospitals (p = 0.006). Among all drugs, treprostinil had the highest availability (56.1% across hospitals), while newer drugs such as selexipag had very low availability (&amp;lt;10%). Price analysis revealed that the DDDc for most drugs had significantly decreased, including sildenafil (\u221291.0%) and macitentan (\u221295.2%), while iloprost remained costly (&amp;gt;3,700 CNY). In terms of affordability, in 2023, all drugs were affordable for the highest-income urban groups, while no drugs were affordable for the lowest-income rural groups, with the cost burden of iloprost accounting for 8,454.8% of the disposable income of the rural population. Drug accessibility exhibited significant structural imbalances, with some drugs being \u201caffordable but hard to obtain\u201d (e.g., riociguat) and others \u201chighly burdensome and poorly accessible\u201d (e.g., treprostinil).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings demonstrate significant improvements in the affordability and availability of PAH-targeted therapies over the study period; however, notable inequalities persist in accessibility improvements across urban and rural areas and income groups. Future policies should be tailored to address specific accessibility challenges for different drug categories and focus on overcoming medication access barriers for low-income rural populations to foster health equity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1671667","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:51:42Z","timestamp":1769071902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A study on the accessibility and utilisation of targeted drugs for pulmonary arterial hypertension in China"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Affiliated Suqian Hospital of Xuzhou Medical University","place":["Suqian, Jiangsu, China"]},{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Group Suqian Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Suqian Hospital of Xuzhou Medical University","place":["Suqian, Jiangsu, China"]},{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Group Suqian Hospital","place":["Suqian, Jiangsu, China"]},{"name":"School of Pharmacy, Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Suqian Hospital of Xuzhou Medical University","place":["Suqian, Jiangsu, China"]},{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Group Suqian Hospital","place":["Suqian, Jiangsu, China"]},{"name":"School of Pharmacy, Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Suqian Hospital of Xuzhou Medical University","place":["Suqian, Jiangsu, China"]},{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Group Suqian Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Suqian Hospital of Xuzhou Medical University","place":["Suqian, Jiangsu, China"]},{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Group Suqian Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyi","family":"You","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Suqian Hospital of Xuzhou Medical University","place":["Suqian, Jiangsu, China"]},{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Group Suqian Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Suqian Hospital of Xuzhou Medical University","place":["Suqian, Jiangsu, China"]},{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Group Suqian Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanquan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Suqian Hospital of Xuzhou Medical University","place":["Suqian, Jiangsu, China"]},{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Group Suqian Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongdou","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Suqian Hospital of Xuzhou Medical University","place":["Suqian, Jiangsu, China"]},{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Group Suqian Hospital","place":["Suqian, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"B1","unstructured":"Reimbursement ratios for outpatient and inpatient medical expenses\n          \n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12939-024-02137-z","article-title":"Analysis of affordability differences for rare diseases in China: a comparison across disease types and regions","volume":"23","author":"Chen","year":"2024","journal-title":"Int. J. Equity Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.15912\/j.cnki.gocm.2023.18.001","article-title":"Analysis on the use and change trend of cardiovascular system medication in outpatient clinics of our hospital in recent years under the background of medical reform","volume":"21","author":"Chen","year":"2023","journal-title":"Chin. Med. Guide"},{"key":"B4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.13653\/j.cnki.jqte.20240226.001","article-title":"Analysis of medical insurance reimbursement benefits and patients' choice of off-site medical treatment\u2014based on spatial distance, hospital level and medical insurance benefits","volume":"41","author":"Chen","year":"2024","journal-title":"J. Quantitative & Tech. Econ."},{"key":"B5","first-page":"437","volume-title":"New edition of pharmacology [M]","author":"Chen","year":"2019"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.2147\/IJGM.S304992","article-title":"Transition from bosentan to ambrisentan in pulmonary arterial hypertension: a single-center prospective study","volume":"14","author":"Chen","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"B7","unstructured":"Analysis report on the implementation of drugs in national medical insurance negotiations over the years\n          \n          \n          2025"},{"key":"B8","unstructured":"White paper on the survival status of pulmonary arterial hypertension patients in China released: revealing the current status of diagnosis and treatment of patient groups\n          \n          \n          2025"},{"key":"B54","article-title":"Making outcome-based payment a reality in the NHS. Phase two: practical considerations","author":"Cole","year":"2021","journal-title":"Grant-Funded Res"},{"key":"B9","volume-title":"How do good health technologies get to poor people in poor countries?","author":"Frost","year":"2009"},{"key":"B10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(24)00295-9","article-title":"Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"13","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41569-024-01064-4","article-title":"Mechanisms and treatment of pulmonary arterial hypertension","volume":"22","author":"Ghofrani","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of Disease study 2019","volume":"396","year":"2020","journal-title":"Lancet."},{"key":"B13","first-page":"1639","article-title":"International drug reimbursement policy for pulmonary hypertension treatment and its enlightenment to China","volume":"50","author":"Guan","year":"2015","journal-title":"Chin. J. Pharm. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B15","volume-title":"Canada\u2019s national strategy for drugs for rare diseases","year":"2025"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0204206","DOI":"10.1371\/journal.pone.0204206","article-title":"Disease and economic burden for rare diseases in Taiwan: a longitudinal study using Taiwan's national health insurance research database","volume":"13","author":"Hsu","year":"2018","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B18","unstructured":"Understanding pharmaceutical markets in India\n          \n          \n          2025"},{"key":"B19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12913-021-06533-x","article-title":"Trends and determinants of catastrophic health expenditure in China 2010-2018: a national panel data analysis","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Health Serv. Res."},{"key":"B20","first-page":"1111","article-title":"Investigation on the survival status of patients with arterial pulmonary hypertension in China","volume":"37","author":"Luo","year":"2022","journal-title":"Chin. J. Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.mayocp.2020.04.039","article-title":"Pulmonary hypertension: a brief guide for clinicians","volume":"95","author":"Mandras","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"B22","doi-asserted-by":"publisher","first-page":"13319","DOI":"10.3390\/ijerph192013319","article-title":"A cross-sectional study of price and affordability of drugs for rare diseases in Shandong Province, China","volume":"19","author":"Mu","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B23","unstructured":"China statistical yearbook 2024\n          \n          \n          2025"},{"key":"B24","unstructured":"National essential medicines list for basic medical insurance, work injury insurance, and maternity insurance\n          \n          \n          2023"},{"key":"B25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13561-024-00519-1","article-title":"Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review","volume":"14","author":"Ng","year":"2024","journal-title":"Health Econ. Rev."},{"key":"B27","first-page":"833","article-title":"Overview of the medical quality of cardiovascular diseases in China in 2023","volume":"39","year":"2024","journal-title":"Chin. J. Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.19546\/j.issn.1674-3830.2024.7.005","article-title":"Analysis on the allocation of national health insurance negotiated drugs from a multidimensional perspective","author":"Peng","year":"2024","journal-title":"China Health Insur."},{"key":"B29","unstructured":"Popular generic drug reviews\n          \n          \n          2025"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3760\/cma.j.cn112137-20201008-02778","article-title":"Guidelines for the diagnosis and treatment of pulmonary arterial hypertension in China","volume":"101","year":"2021","journal-title":"Chin. Med. J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.13683\/j.wph.2023.06.025","article-title":"Procurement status and affordability analysis of rare disease drugs under national negotiation","volume":"44","author":"Ren","year":"2023","journal-title":"World Clin. Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"B33","unstructured":"Brief introduction to CMEI\n          \n          \n          2025"},{"key":"B34","volume-title":"Pulmonary hypertension - arterial","year":"2021"},{"key":"B35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40545-021-00339-2","article-title":"Availability, pricing and affordability of essential medicines in Eastern Ethiopia: a comprehensive analysis using WHO\/HAI methodology","volume":"14","author":"Sisay","year":"2021","journal-title":"J. Pharm. Policy Pract."},{"key":"B36","volume-title":"National healthcare security statistics bulletin","year":"2024"},{"key":"B37","unstructured":"Announcement of the state food and drug administration and the national health commission on the release of the 2020 edition of the Pharmacopoeia of the People'S Republic of China\n          \n          \n          2025"},{"key":"B38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1253\/circj.CJ-17-0139","article-title":"Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension","volume":"82","author":"Tamura","year":"2017","journal-title":"Circ. J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.zefq.2014.06.017","article-title":"The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand","volume":"108","author":"Teerawattananon","year":"2014","journal-title":"Z Evid. Fortbild. Qual. Gesundhwes"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3969\/j.issn.1008-1070.2024.12.016","article-title":"Analysis and prediction of the trend of mortality level and disease burden in patients with arterial pulmonary hypertension in China from 1992 to 2021","volume":"59","author":"Wang","year":"2024","journal-title":"Chin. Med. J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"646494","DOI":"10.3389\/fpubh.2021.646494","article-title":"Impact of catastrophic health expenditures on Chinese household consumption","volume":"9","author":"Wei","year":"2021","journal-title":"Front. Public Health"},{"key":"B42","unstructured":"ATC\/DDD Index 2022\n          \n          \n          2025"},{"key":"B43","volume-title":"World health statistics 2021: monitoring health for the SDGs, sustainable development goals","year":"2021"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.28207\/n.cnki.ndycj.2023.003300","article-title":"Seventy percent of the listed rare disease drugs are included in the basic medical insurance the problem of \u201cdifficult drug use\u201d for patients is still severe [N]","author":"Wu","year":"2025","journal-title":"Yicai Dly. 2023-08-10(A06)"},{"key":"B45","unstructured":"From the perspective of drug accessibility, the \u201clast mile\u201d of national drug landing\n          \n          \n            \n              Wu\n              J.\n            \n            \n              Jiang\n              X. Y.\n            \n            \n              Xu\n              X. Y.\n            \n          \n          \n          2025"},{"key":"B46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13023-016-0454-7","article-title":"Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China","volume":"11","author":"Xin","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e70175","DOI":"10.1002\/mco2.70175","article-title":"The challenge in burden of pulmonary arterial hypertension: a perspective from the global burden of disease study","volume":"6","author":"Yang","year":"2025","journal-title":"MedComm"},{"key":"B48","unstructured":"Notice on improving the outpatient treatment coverage mechanism for nationally negotiated drugs during the agreement period\n          \n          \n          2025"},{"key":"B49","first-page":"2920","article-title":"Application of cardiovascular drugs in a hospital in Nanjing under the background of national centralized procurement","volume":"20","author":"Zhang","year":"2022","journal-title":"Zhongnan Pharm."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.13286\/j.1001-5213.2022.13.05","article-title":"Cost-effectiveness analysis of targeted therapeutic drugs for pulmonary arterial hypertension based on markov model","volume":"42","author":"Zhao","year":"2022","journal-title":"Chin. J. Hosp. Pharm."},{"key":"B51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.15973\/j.cnki.cn11-3708\/d.2021.06.039","article-title":"Outpatient reimbursement and patient rights in pulmonary hypertension","author":"Zhu","year":"2021","journal-title":"China Health"},{"key":"B52","first-page":"1598","article-title":"Study on the choice behavior and influencing factors of multi-morbidity patients in medical institutions under the background of hierarchical medical treatment","volume":"26","author":"Zhu","year":"2023","journal-title":"Chin. General Pract."},{"key":"B53","first-page":"1473","article-title":"Cross-sectional investigation on the affordability of original and generic antihypertensive drugs in Shaanxi Province before and after the national centralized drug procurement","volume":"42","author":"Zou","year":"2023","journal-title":"Her. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1671667\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:45:22Z","timestamp":1771919122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1671667\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":53,"alternative-id":["10.3389\/fphar.2026.1671667"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1671667","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"article-number":"1671667"}}